Amneal Pharmaceuticals (NASDAQ:AMRX) PT Raised to $12.00 at Truist Financial

Amneal Pharmaceuticals (NASDAQ:AMRXGet Free Report) had its target price hoisted by analysts at Truist Financial from $10.00 to $12.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 40.35% from the company’s current price.

A number of other research analysts have also issued reports on AMRX. JPMorgan Chase & Co. raised shares of Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price for the company in a research note on Friday, September 6th. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $9.40.

Check Out Our Latest Research Report on Amneal Pharmaceuticals

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $8.55 on Wednesday. Amneal Pharmaceuticals has a 52 week low of $3.36 and a 52 week high of $8.94. The company has a market cap of $2.64 billion, a PE ratio of -15.27 and a beta of 1.18. The company has a current ratio of 1.33, a quick ratio of 0.82 and a debt-to-equity ratio of 121.31. The company’s fifty day simple moving average is $8.14 and its 200-day simple moving average is $7.05.

Amneal Pharmaceuticals (NASDAQ:AMRXGet Free Report) last released its quarterly earnings results on Friday, August 9th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.04. The firm had revenue of $701.78 million for the quarter, compared to the consensus estimate of $657.43 million. Amneal Pharmaceuticals had a negative net margin of 6.72% and a positive return on equity of 1,235.03%. As a group, equities research analysts anticipate that Amneal Pharmaceuticals will post 0.52 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AMRX. Rothschild Investment LLC bought a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $26,000. DekaBank Deutsche Girozentrale bought a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $42,000. Atlanta Consulting Group Advisors LLC bought a new position in shares of Amneal Pharmaceuticals during the first quarter valued at $61,000. nVerses Capital LLC bought a new position in shares of Amneal Pharmaceuticals during the second quarter valued at $62,000. Finally, Trexquant Investment LP bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at $65,000. 31.82% of the stock is owned by institutional investors.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.

Read More

Analyst Recommendations for Amneal Pharmaceuticals (NASDAQ:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.